Anne Coleman to Antineoplastic Agents, Immunological
This is a "connection" page, showing publications Anne Coleman has written about Antineoplastic Agents, Immunological.
Connection Strength
0.223
-
Population-Based Frequency of Ophthalmic Adverse Events in Melanoma, Other Cancers, and After Immune Checkpoint Inhibitor Treatment. Am J Ophthalmol. 2021 04; 224:282-291.
Score: 0.179
-
Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry. Ophthalmology. 2021 06; 128(6):910-919.
Score: 0.044